April 26 (Reuters) - Ista Pharmaceuticals Inc. (ISTA.O: Quote, Profile, Research, Stock Buzz) on Thursday said it expects its 2007 gross margin of 70 to 74 percent.
In a conference call, the ophthalmic pharmaceutical company said it continues to expect 2007 research and development expense of $24 million to $28 million. (Reporting by Niveditha Ravi in Bangalore)
© Thomson Reuters 2008 All rights reserved
A selection of our best photos from the past 24 hours. View Slideshow
McCain, Obama spar over tax plans
Banking on the short term
The debate over Bush
Candidates battle over Ayers, ACORN
Thailand says its 'ready for war'
Talk of the Town:Splitsville!
Containing California's wildfires
Cheney heads to hospital
McCain offers his own economic plan
Mass grave uncovered in Iraq
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Interactive TV |
Labs |
Reuters in Second Life |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
economic plan
